BrainStorm Cell Therapeutics (otcqb:BCLI), a developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company an additional patent for its autologous stem cell technology. The patent (No. 8, 647, 874) covers the production method of the company’s proprietary stem cells induced to secrete significantly elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
The neurotrophic factors secreted by the company’s patented cells include Glial Cell-Derived Neurotrophic Factor (GDNF), Brain-Derived Neurotrophic Factor (BDNF), and Vascular Endothelial Growth Factor (VEGF), known to support the neural cell network by protection of existing motor neurons, promotion of motor neuron growth, and re-establishment of nerve-muscle interaction. In addition, the cells secrete high levels of Hepatocyte Growth Factor (HGF), which has been recently suggested to have neuroprotective effects in ALS.
–
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Neurons from Stem Cells (Brainstorm Ep4)
–
BrainStorm is the exclusive worldwide licensee of this technology from Ramot, the technology transfer company of Tel Aviv University, where it was developed by Professors Daniel Offen and Eldad Melamed, in conjunction with BrainStorm’s scientists.
About BrainStorm Cell Therapeutics, Inc. holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.
